

Corilagin Potential in Inhibiting Stress Oxidative and Inflammatory in LPS-induced Murine Macrophage Cell Lines (RAW 264.7)

Wahyu Widowati^{1*}, Hanna Sari Widya Kusuma², Seila Arumwardana², Ervi Afifah², Cintani Dewi Wahyuni², Cahyaning Riski Wijayanti², Muhamad Aldi Maulana², Rizal Rizal^{2,3}

¹Faculty of Medicine, Maranatha Christian University, Jl. Surya Sumantri No. 65, Bandung 40164, West Java, Indonesia

²Biomolecular and Biomedical Research Center, Aretha Medika Utama, Jl Babakan Jeruk II No. 9, Bandung 40163, West Java, Indonesia

³Biomedical Engineering, Department of Electrical Engineering, Faculty of Engineering, Universitas Indonesia, Depok 16426, West Java, Indonesia

Running title: Corilagin Inhibiting Stress Oxidative and Inflammation

*Corresponding author: Wahyu Widowati, Medical Research Center, Faculty of Medicine, Maranatha Christian University, Prof. Drg. Suria Sumantri 65, Bandung, 40164, West Java, Indonesia

Tel: +6281910040010

Email: wahyu_w60@yahoo.com

Manuscript ID: IJBMS-2107-13174

Manuscript Title: **Corilagin Potential in Inhibiting Stress Oxidative and Inflammatory in LPS-induced Murine Macrophage Cell Lines (RAW 264.7)**

Authors: Wahyu Widowati

Dear Dr **Dr. Wahyu Widowati**

I wish to acknowledge the receipt of the above mentioned manuscript.

Submission of a manuscript to the Iranian Journal of Basic Medical Sciences (IJBMS) implies that the work reported therein has not received prior publication and is not under consideration for publication elsewhere in any medium, including electronic journals and computer databases of a public nature. This manuscript is being considered with the understanding that it is submitted on an exclusive basis.

Also please note that according to the Committee on Publication Ethics (COPE) guidelines, all authors must have reviewed and approved the submission of their manuscript. Accepted manuscripts cannot be withdrawn, once this decision has been reached. If you are a coauthor and approve its submission, no action is necessary. If you do not approve its submission to IJBMS, please let us know as soon as possible. Refer to the manuscript number listed above in any correspondence, or you may simply reply to this message leaving the subject line intact. For more information on ethical responsibilities of authors, see Ethical Consideration in "Guide for Authors" section of Journal at <http://ijbms.mums.ac.ir/journal/authors.note>

All the manuscript submitted to IJBMS are checked by authenticate for possible plagiarism. The authors are expected to check their manuscript for plagiarism before submission. In publishing only original research, IJBMS is committed to deterring plagiarism, including self-plagiarism.

Please noted that:

Starting with July 2020 IJBMS levies an article-processing charge of 15.000.000 Rls. for each original and short communication article accepted for publication. Please note that these charges apply only to accepted articles of Iranian authors. All other articles are exempt from these charges.

Our editorial decision will be brought to your attention once the paper has been reviewed due the reviewer considerations.

Regards

Bibi Sedigheh Fazly Bazzaz, Ph.D.

Editor-in-Chief
Iranian Journal of Basic Medical Sciences

<http://ijbms.mums.ac.ir>

Tel: +98-5131801510 Fax: +98-5138823251

E-mail: jbms@mums.ac.ir

Comments to the authors:

Authors studied Corilagin Potential in Inhibiting Stress Oxidative and Inflammatory in LPS-induced Murine Macrophage Cell Lines (RAW 264.7). The study is interesting but some of point should be addressed in the manuscript.

- Abstract: This section is good
- Introduction is non-professionally written, pretty long and boring. Specifically, better/professional paragraphing is necessary to become less boring and more reader friendly.
- There are spelling and abbreviation errors in your article
- Methods: This section is good.
- Results: This section is good.
- Discussion: This section is good.
- Conclusion: should be added contributions for future studies

Answer

Dear Sir/Madam (The Reviewer)

Thank you very much for the evaluation and input for the improvement for our manuscript.

The following revision has been done based on the comment in our manuscript

1. The introduction section has been changing to be shorter.
2. Spelling and abbreviation errors has been checked.
3. The future contribution of this study has been added in conclusion.

ABSTRACT

Objective(s): Inflammation is thought to be the common pathophysiological basis for several disorders. Corilagin is one of the major active compounds which showed broad-spectrum biological, and therapeutic activities, such as antitumor, hepatoprotective, antioxidant, anti-inflammatory actions. This study aimed to evaluate the antioxidant and anti-inflammatory activities of corilagin in LPS-induced RAW264.7 cells.

Materials and Methods: Antioxidant activities were examined by free radical scavenging of H₂O₂, NO, and OH. The safe concentrations of corilagin on RAW264.7 were determined by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay on RAW264.7 cell lines. The inflammation cells model induction by LPS. The anti-inflammatory activities were measured the IL-6, TNF- α , NO, IL-1 β , PGE-2, iNOS, and COX-2 levels using ELISA assay.

Results: The results showed that corilagin had a significant inhibition activity in a dose-dependently in scavenging activities toward H₂O₂, OH, and NO with IC₅₀ values were 76.85 μ g/mL, 26.68 μ g/mL, and 66.64 μ g/mL, respectively. The anti-inflammatory activity of corilagin also showed a significant decrease toward IL-6, TNF- α , NO, IL-1 β , PGE-2, iNOS, and COX-2 levels at the highest concentration (75 μ M) compared to others concentration (50 and 25 μ M) with the highest inhibition activities were 48.09%, 42.37%, 65.69%, 26.47%, 46.88%, 56.22%, 59.99%, respectively ($p < 0.05$).

Conclusion: Corilagin has potential as antioxidant and anti-inflammatory in LPS-induced RAW 264.7 cell lines by their ability to scavenging free radical NO, OH, and H₂O₂ and also suppresses the production of proinflammatory mediators including COX-2, IL-6, IL-1 β , and TNF- α in RAW 264.7 murine macrophage cell lines.

Keywords: Antioxidant, anti-inflammatory, corilagin, LPS, RAW 264.7

Introduction

Over the past two years, inflammation has become a medical concern for researchers, especially those related to COVID-19. Inflammation is a complex mechanical process involved in various compounds. Inflammation is a response to irritation and infection caused by pathogens, injury, and chemicals (1,2). Reactive oxygen species (ROS) such as anion superoxide ($O_2^{\bullet-}$), hydroxyl radical ($^{\bullet}OH$), peroxide radicals (ROO), and nitric acid radical (NO) are key signaling molecules that contribute to the progression of inflammatory diseases (3,4).

Antioxidants are the components to neutralize the effect of free radicals, but the effect will be limited to specific antioxidants (5). The antioxidant agent plays an important role in setting up this intricate balance in the cells (6). The natural bioactive compounds in various plants have an antioxidant activity. It may help in preventing several inflammatory diseases free-radical scavenging activity (7). Corilagin was isolated from *Caesalpinia coriaria* (Jacq.) Willd. (dividivi) by Schmidt in 1951 for the first time (8). Corilagin was reported to exhibit antioxidant (9), anti-cancer (7), anti-inflammatory, and hepatoprotective activities (10). The previous reports have appeared that corilagin can inhibit Tumor Necrosis Factor- α (TNF- α) expression and radiation-stimulated microglia activation by controlling the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF- κ B) pathway (11). Corilagin also has the potential to remedy inflammation and oxidation-related diseases through the capability toward hepatic protection, by blocking the NF- κ B pathway, has anti-oxidative effects, and can act as a hepatoprotective agent (10).

Based on potential of corilagin, this study evaluates the antioxidant and anti-inflammatory activities of corilagin through scavenger ability on H_2O_2 , OH, NO, and also inhibitory activity of pro-inflammatory mediators including iNOS, COX-2, IL-6, IL-1 β , and TNF- α in LPS-induced macrophage cells.

Materials and Methods

H₂O₂ scavenging activity assay

Ferrous ammonium sulfate (1 mM, 12 μ L), samples at various concentrations, and H₂O₂ (5 mM, 3 μ L) were transferred into a 96-well plate and incubated at room temperature for 5 min. Then, 75 μ L of 1,10-phenanthroline was added, and the plate was incubated again for 10 minutes in the same condition (12,13). The mixture absorbance was read using a microplate reader at a wavelength of 510 nm and expressed as a percentage of H₂O₂ scavenging activity, which was computed using the equation below:

$$\% \text{ H}_2\text{O}_2 \text{ Scavenging Activity} = (1-(A_s/A_c)) \times 100$$

Ac: Absorbance of negative control

As: Sample absorbance

OH scavenging activity assay

The reaction mixture contained 30 μ L of different concentrations of sample, 10 μ L of FeCl₃-EDTA (Merck, 1.039430250;), 5 μ L of 20 mM H₂O₂ (Merck, 822287), 5 μ L of 1 mM L-Ascorbic acid (Sigma-Aldrich, K3125), 10 μ L of 28 Mm Deoxyribose (Sigma-Aldrich, 121649), and 70 μ L phosphate buffer. The mixture was incubated at 37 °C for 30 min and then 25 μ L of 5% TCA (Merck, 1008070250), and 1% TBA (Sigma-Aldrich, T5500) were added to be further incubated at 80–90°C for 30 min. The absorbance was measured at 532 nm wavelength using a spectrophotometer (14).

RAW264.7 cell culture

The RAW 264.7 (ATCC®TIB-71™) murine macrophage cell line was obtained from Biomolecular and Biomedical Research Center, Aretha Medika Utama. RAW 264.7 cells were grown in Dulbecco's Modified Eagle Medium (DMEM) (Biowest, L0104) supplemented with

10% fetal bovine serum (FBS) (Biowest, S1810) and 1% antibiotic–antimycotic (Gibco, Massachusetts, USA, 15240062). The cells were incubated at 37 °C and 5% CO₂ in the humidified atmosphere until confluent (80%–90%). Trypsin-EDTA 0.25% (Gibco, 25200072) was used to harvest the cells which were then seeded on plates for the assays (2,8,15–18).

Viability assay

The cytotoxicity of corilagin was determined by the viability of RAW 264.7 cells using MTS assay (Promega, Madison, G3580). This method determines the safe and nontoxic the concentration of sample for the next assay. Briefly, 100 µL cells (5×10^3 cells per well) in medium (DMEM supplemented with 10% FBS and 1% penicillin-streptomycin) were plated in a 96-well plate and incubated for 24 hours at 37°C in a humidified atmosphere incubator with 5% CO₂. The medium was then washed and added with 99 µL new medium and 1 µL of corilagin in different concentrations and DMSO in triplicate then the plate was incubated for 24 hours. Untreated cells were served as the control. Briefly, 20 µL MTS was added to each well. The plate was incubated in 5% CO₂ at 37°C incubator for 4 hours. The absorbance was measured at 490 nm on a microplate reader (2,8,15–19).

Proinflammatory activation of RAW264.7 cell lines

The cells were seeded in a 6-well plate in the density of 5×10^5 cells per well and incubated for 24 hours at 37°C in a humidified atmosphere and 5% CO₂. The medium (DMEM supplemented with 10% FBS and 1% penicillin-streptomycin) was then washed and supplemented with 1,600 µL growth medium and 200 µL corilagin (75, 50, 25 µM). Around 1-2 hours later, the medium was added with 200 µL lipopolysaccharide from *Escherichia coli* (LPS) (1 µg/mL) (Sigma-Aldrich, L2630) and incubated for 24 hours at 37°C in a humidified atmosphere and 5% CO₂. After incubation of RAW 264.7 cells with LPS for 24 hours, the

quantity of IL-6, TNF- α , NO, IL-1 β , PGE-2, iNOS, and COX-2 was accumulated in the cell-free supernatant. The cell-free supernatant then was taken for the next assay by centrifugation at 2,000 g for 10 minutes. The supernatant was stored at -79 °C for measuring the IL-6, TNF- α , NO, IL-1 β , PGE-2, iNOS, and COX-2 level (2,15,17–19).

Quantification of IL-1 β , TNF- α , COX-2, IL-6, PGE-2, iNOS level in LPS-Induced RAW 264.7 cells

The IL-1 β , TNF- α , COX-2, IL-6, PGE-2, iNOS levels were assayed using ElabScience Elisa Kit IL-1 β (E-EL-M0037), TNF- α (E-EL-M0049), COX-2 (E-EL-M0959) IL-6 (E-EL-M0044), PGE-2 (E-EL-0034), and iNOS (E-EL-M0696), based on manufacture protocols (2,8,15–20).

Quantification of NO level in LPS-Induced RAW 264.7 cells

The nitrite associated with NO production was measured using NO Colorimetric Assay (ElabScience, E-BC-K035-M) that was performed based on manufacturing protocols. The Sodium Nitrite Standard curve was determined to measure the nitrite quantity (17).

Total protein assay

Bovine Standard Albumin (BSA) standard solution was made from dilution series of BSA stock. The stock was obtained by dissolving 2 mg of BSA (Sigma Aldrich, A9576) in 1000 μ L ddH₂O, briefly, 20 μ L of standard solutions and 200 μ L Quick Start Dye Reagen 1X (Biorad, 5000205) was added into each well plate. After 5 min of incubation at room temperature, absorbance was measured by a microplate reader at 595 nm (19,20).

Statistical analysis

All data were obtained after doing it in triplicate. The data were presented as mean \pm standard deviation. The data were analyzed using ANOVA and Post Hoc Test using Tukey HSD with $p < 0.05$ using SPSS software (version 20.0).

Results

Effect of corilagin on H₂O₂ scavenging activity

Effect of corilagin treatments in H₂O₂ scavenging activity has been performed in **Figure 1**. Based on **Figure 1**, The corilagin treatment in concentration 500 $\mu\text{g/mL}$ showed a significant increase in the inhibitory activity ($94.86 \pm 4.90\%$) compared to other treatment concentrations in H₂O₂ scavenging activity ($p < 0.05$). Corilagin also has an IC₅₀ value of H₂O₂ scavenging activity with a value of 76.85 $\mu\text{g/mL}$ (**Table 1**). This indicates corilagin has antioxidant activity due to H₂O₂ scavenging activity.

Effect of corilagin on OH scavenging activity

The effect of corilagin treatments in the scavenging activity of OH can be seen in **Figure 2**. The inhibitory activity of corilagin shows that the highest activity in concentration 26.67 $\mu\text{g/mL}$ with a value of $49.30 \pm 3.34\%$ ($p < 0.05$). Corilagin also has an IC₅₀ value of H₂O₂ scavenging activity with a value of 26.68 $\mu\text{g/mL}$ (**Table 2**). That indicated corilagin has antioxidant properties through scavenging OH free radicals.

Effect of corilagin on NO scavenging activity

Effect of corilagin treatments in NO scavenging activity exhibited in **Figure 3**. The inhibitory activity of corilagin shows that the highest activity in concentration 66.67 $\mu\text{g/mL}$ with a value of $49.73 \pm 7.38\%$ ($p < 0.05$). In **Table 3**, the IC₅₀ value of corilagin as NO scavenger is 66.64 $\mu\text{g/mL}$. This indicated corilagin has NO scavenging activity.

Effect of corilagin toward RAW264.7 cells viability

The viability of RAW264.7 cell lines is presented in **Table 4**. The increased concentration was correlated with increasing toxicity (<90% viability cells). **Table 4** shows the cytotoxicity of corilagin concentration on RAW264.7 cell lines. The viability of cells was decreased in a dose-dependent manner. In concentration 100 µg/mL demonstrated the lowest viability of cells by corilagin with a value of $78.96 \pm 4.46\%$ ($p < 0.05$).

Effect of corilagin toward IL-6 level in LPS-induced cells

Essential proinflammatory cytokine expression of IL-6 in LPS-induced cells was measured (**Figure 4**). As shown in **Figure 4A**, LPS (1 µg/mL) administration for 24 h significantly increased this cytokine (635.95 ± 57.77 pg/mL) compared with the negative control group (167.95 ± 27.74 pg/mL). Corilagin treatment in 75 µM exhibited the decrease of IL-6 level (330.14 ± 33.03 pg/ml; 1523.36 ± 152.42 pg/mg protein) and also showed the highest increase in inhibitory activity in IL-6 level ($48.09 \pm 5.19\%$) compared to positive control and other treatments ($p < 0.05$) (**Figure 4A-C**).

Effect of corilagin toward TNF-α level in LPS-induced cells

The cytokine expressions of TNF-α in LPS-induced cells was shown in **Figure 5**. Corilagin at concentration 75 µM resulted significant decrease TNF-α level (279.61 ± 24.95 pg/mL; 129.02 ± 11.51 pg/mg protein). The result was comparable with negative control (218.18 ± 9.41 pg/mL; 106.10 ± 4.58 pg/mg protein) which indicates the treatment has good anti-inflammatory (**Figure 5A and 5B**). The inhibitory activity of TNF-α also shows the highest presentation ($42.37 \pm 5.14\%$) compared to other treatments and positive control ($p < 0.05$) (**Figure 5C**).

Effect of corilagin toward NO level in LPS-induced cells

The effect of corilagin treatment toward NO level in LPS-induced cells has been shown in **Figure 6**. Corilagin resulted from the lowest NO level at the highest concentration (75 μM) with a value of $11.82 \pm 2.95 \mu\text{M}$; $54.53 \pm 13.60 \mu\text{M}/\text{mg}$ protein with inhibitory activity $65.69 \pm 8.56\%$ compared to control and other treatments ($p < 0.05$) (**Figure 6A-C**). The results demonstrated that corilagin possessed antioxidant activity.

Effect of corilagin toward IL-1 β level in LPS-induced cells

The effect of corilagin toward level and inhibitory activity of IL-1 β has been shown in **Figure 7**. There were significant ($p < 0.05$) decrease in level of IL-1 β ($890.00 \pm 29.46 \text{ pg}/\text{mL}$; $410.67 \pm 13.59 \text{ pg}/\text{mg}$ protein) (**Figure 7A and 7B**) and increase in inhibitory activity of IL-1 β ($26.47 \pm 2.43\%$) in the highest concentration of corilagin treated group compared to positive control ($1210.31 \pm 9.57 \text{ pg}/\text{mL}$; $0.00 \pm 0.79\%$, respectively) (**Figure 7A and 7C**).

Effect of corilagin toward PGE-2 level in LPS-induced cells

In the LPS group (positive control) the PGE-2 level was significantly increased ($903.15 \pm 120.07 \text{ pg}/\text{mL}$) when compared with the negative control group ($429.42 \pm 36.87 \text{ pg}/\text{mL}$) ($p < 0.05$). With corilagin intervention, PGE-2 level expression was significantly reduced in the highest concentration ($479.76 \pm 15.99 \text{ pg}/\text{mL}$; $2,213.74 \pm 73.77 \text{ pg}/\text{mg}$ protein) (**Figure 8A and 8B**) and has an inhibitory percentage of $46.88 \pm 1.77\%$ when compared with the LPS group ($p < 0.05$) (**Figure 8C**).

Effect of corilagin toward iNOS level in LPS-induced cells

The effect of corilagin on the iNOS level has been shown in **Figure 9**. The level of iNOS in the positive control group significantly increased before being stimulated by LPS (negative

control) with values 11.35 ± 0.45 and 3.16 ± 0.04 ng/mL, respectively. Corilagin treatment showed the lowest iNOS level in concentration 75 μ M with value 4.97 ± 0.09 ng/mL; 2.42 ± 0.04 ng/mg protein ($p < 0.05$) compared to another group (**Figure 9A and 9B**). Corilagin also has the highest inhibitory activity compared to positive control with a value of $56.22 \pm 0.81\%$ (**Figure 9C**).

Effect of corilagin toward COX-2 level in LPS-induced cells

The effect of corilagin on the COX-2 level has been shown in **Figure 10**. In the positive control group, the COX-2 level was significantly increased (9.94 ± 0.60 ng/mL) when compared with the negative control group (2.44 ± 0.03 ng/mL) ($p < 0.05$) (**Figure 10A**). COX-2 level expression was significantly reduced in the highest concentration (75 μ M) with a value of 3.98 ± 29.46 ng/mL; 1.93 ± 0.29 ng/mg protein compared with other treatment and also has inhibitory activity with value $59.99 \pm 6.09\%$ ($p < 0.05$) (**Figure 10A-C**). **Figure 11** shows effect various concentrations of corilagin toward cells morphological, density in LPS-induced RAW 264.7 cells line.

Discussion

Corilagin is a phenolic compound that has been reported to show promising pharmacological effects including anti-inflammatory and antioxidant (8, 21). In antioxidant activity, corilagin in concentration showed a significant increase in H₂O₂ scavenging activity ($94.86 \pm 4.90\%$) (**Figure 1**). Previous study show corilagin has slightly higher than the standard (Vitamin C) and depend of concentration (22).

Free radicals such as hydroxyl radicals (OH) and superoxide anion radicals can be generated by normal physiological reactions in living organisms (23). In recent studies, corilagin has OH inhibitory activity in a dose-dependent manner with the highest value (49.30

$\pm 3.34\%$) (**Figure 2**). In another study has been reported that corilagin isolated from longan pericarp extract possessed the highest OH inhibitory rate of $75.90 \pm 0.30\%$ compared to other phenolic compounds, and also has DPPH radical scavenging rate of $71.80 \pm 0.50\%$ (24). Corilagin showed antioxidative activity due to scavenging of nitrite and blocking of nitrosamine synthesis (8). Corilagin significantly reduces oxidative stress by increasing the total antioxidant capacity and decreasing malondialdehyde (MDA) in the spinal tissue injured rat. Corilagin treatment also decreases the concentration of cytokines in the spinal tissue than spinal cord injured rats. Oxidative stress and inflammatory mediators trigger the activity of caspase cascade and result in increased activity of caspase 3, Bax, and a decrease in Bcl-2 in injured spinal cord tissues (25).

The antioxidant effect of corilagin also was measured by their inhibitory potency on nitric oxide (NO). In this study, corilagin shows the highest NO scavenging activity is $49.73 \pm 7.38\%$ in a concentration of $66.67 \mu\text{g/mL}$ ($p < 0.05$) (**Figure 3**). Corilagin show to exhibit NO scavenging activity with IC_{50} $7.2 \mu\text{M}$ (26).

In this study, the cytotoxic assay was performed on RAW 264.7 cells to rule out any adverse effects before using corilagin. Based on the results of cytotoxic (viability cell) assays, corilagin treatment showed not toxic and safe in concentrations 75, 50, and 25 μM .

LPS-induced in macrophage cell lines (RAW 264.7) as proinflammatory activation caused the increase in inflammatory cytokines are IL-6, TNF- α , NO, IL-1 β , PGE-2, iNOS, and COX-2 (2, 7.8, 8.20, 9.15, 10.16, 12.17, 25.18, 26.19). In this study, the inflammation model using LPS-induced cells as a positive control indicated increasing of inflammatory cytokines such as IL-6, TNF- α , NO, IL-1 β , PGE-2, iNOS, and COX-2 compared to the negative control. Macrophages become activated and produce proinflammatory mediators through the extracellular region of Toll-Like receptor 4 (TLR4), which will become activated of MAPK (JNK, ERK1/2, p38) pathway (17, 27). The activated TLR4 will activate cascades events in the

cytoplasm which leads to MAPK (JNK, ERK1/2, p38) pathway activation. The phosphorylation of MAPKs allows the inhibitory factor kappa B (I κ B) to be phosphorylated. Nuclear factor-kappa B (NF- κ B) is activated and translocated to the nucleus as a result of this. NF κ B is a widely distributed transcription factor that regulates the expression of genes involved in apoptosis, immune responses, and the cell cycle (17, 28).

IL-6 is a monocyte-derived cytokine, these have an important acute phase reaction medium in inducing the inflammation process (29). Corilagin treatment in a concentration of 75 μ M showed the highest inhibitory activity in the IL-6 level ($48.09 \pm 5.19\%$) compared to positive control and other treatments (**Figure 4C**). Corilagin possessed the anti-inflammatory capability through intervention the expression of TLR4 was greatly decreased in the inflammatory phase. Corilagin intervention, IL-1 β and IL-6 expression was significantly reduced when compared with the LPS group ($p < 0.01$) (30).

TNF- α is a highly inflammatory cytokine developed and secreted by mast cells and plays a key role in some pathogenesis (31, 8, 17). In the present study, we have demonstrated that corilagin has anti-inflammatory activity due to suppressing of TNF- α level ($42.37 \pm 5.14\%$) compared to other treatments (**Figure 5C**). This result is in line with Gambari et al. (2012) study that corilagin can inhibit the expression of (TNF- α) and interleukin (IL)-6 protein (32).

Several mediators, including nitric oxide (NO), control leukocyte recruitment to the infection site. NO is a vascular tone regulator that also controls leukocyte adherence in blood micro-capillaries (33, 34, 35). In NO level, corilagin can suppress NO level with a percentage of 65.69 ± 8.56 (**Figure 6C**). The previous reports demonstrated that corilagin suppresses the levels of NO and modulate oxidative stress to reduce liver damage induced by HCV proteins (36). Corilagin also elicited prominent anti-inflammatory activity in RAW264.7 macrophages via suppressing the LPS-induced TLR4 and NOX2 activation, thereby repressing the

corresponding ROS production, MAPKs activation, and NF- κ B translocation from the cytoplasm to the nucleus, where it mediates the expression of pro-inflammatory mediators, such as TNF- α , IL-6, NO, and PAI-1 in activated macrophage cells (37). Moreover, corilagin lightened the herpes simplex virus (HSV)-1-induced inflammatory damage by inducing the apoptosis of infected microglial cells and inhibiting the production of TNF- α , NO, and IL-1 β (38).

IL-1B production caused Toll-like receptor (TLR) activation and also stimulate upregulation of NF- κ B in inflammatory diseases (39). This study demonstrated that corilagin has an inhibitory activity of IL-1 β ($26.47 \pm 2.43\%$) (**Figure 7C**). Corilagin in pomegranate fruit has been shown to inhibit inducible nitric oxide synthase expression and IL-1B-induced tissue destruction in periodontitis (40).

Prostaglandin E2 (PGE2) is a pro-inflammatory lipid mediator produced by cyclooxygenase-2 (COX-2) and microsomal PGE synthase-1 from arachidonic acid (mPGES-1) (41). The present study was presented that corilagin can act as a PGE-2 inhibitor ($46.88 \pm 1.77\%$) (**Figure 8C**). Phenolic compounds like corilagin can reduce LPS-stimulated PGE₂ production, they exhibit anti-inflammatory activity by targeting different inflammation-related cytokines (42).

Inflammatory activity is accompanied by inducible nitric oxide synthase (iNOS), which produces nitric oxide, which stimulates COX-2 catalytic activity by forming peroxynitrite anion. (43, 44). Stimuli that increase NOS-2 and NO formation also may induce COX-2 expression (44). In this study, iNOS proinflammatory activity has a percentage of $56.22 \pm 0.81\%$ (**Figure 9C**), while COX-2 level has a value is $59.99 \pm 6.09\%$ (**Figure 10C**), all have the highest value compared to positive control and other concentration in LPS-induced cells. Similar results were obtained by Zhao et al. (2008), who found that corilagin repressed the discharge of the pro-inflammatory cytokines COX-2 and NO (iNOS) through inhibiting the

NF- κ B pathway in LPS-stimulated RAW 264.7 (45). Corilagin also can inhibit the production of pro-inflammatory cytokines and mediators including COX-2 through suppressing the DSBs (DNA double-strand breaks)-triggered NF- κ B signaling pathway in the murine microglial cell line (BV-2) (46).

The morphological change in macrophage RAW 264.7 cells induced by LPS and treated with various concentrations of corilagin (75, 50, 25 μ M), furthermore incubated for 24 hours. (**Figure 11**). The negative control (normal cells, without LPS) was a round shape, the positive control became irregularly shape, and increased spreading after LPS stimulation. The cotreatment with 25, 50, 75 μ M corilagin decreased the degree of cell spreading and irregularly shape. Treatment of 75 μ M corilagin was the most active to decrease the spreading and density of cells. This result data was in line with previous research that LPS stimulation changes the round shape become irregularly cells, and increase the spreading cells.

The antioxidant activities possibly contribute to the polyphenol compound found in corilagin, major active polyphenolic tannins (26). Oxidative stress has played a role in activating signal pathways such as NF- κ B, an important transcription factor in the nucleus. The excessive oxidative stress release caused NF- κ B activation, and then nuclear translocation and binding specific sites in the promoter regions of target genes. It up-regulates gene expressions of numerous proinflammatory cytokines and inflammatory mediators including TNF- α , IL-1 β , and COX-2 (47, 48, 49). However, corilagin has protective effects against LPS-induced RAW264.7 cell lines by suppressing ERK/JNK MAPK and NF- κ B signaling pathways. Moreover, the inflammatory mediators and reactive oxygen species (ROS) have been related to the actuation of mitogen-activated protein kinase (MAPK) that controls intracellular signal transduction pathway in oxidative stress-induced cells (50). Its mechanism is attributed to anti-inflammatory and antioxidative properties (37). In summary, corilagin may play a critical part in the oxidative stress and inflammatory response (51). According to these results, we proposed

the mechanism of antioxidant and anti-inflammatory of corilagin in LPS-stimulated RAW264.7 cells (**Figure 12**).

Conclusion

Corilagin has the potential as an antioxidant as measured through H₂O₂, NO, and OH inhibitory activities. Corilagin also has anti-inflammatory properties through suppression of IL-6, TNF- α , NO, IL-1 β , PGE-2, iNOS, and COX-2 levels. However, corilagin protects against LPS-stimulated RAW264.7 cells via inhibiting oxidative stress and inflammation. **This study can be contributed as basic for further research on the exploration of the bioactivity of corilagin and on the treatment of inflammatory diseases with natural compounds.**

Acknowledgments

The authors gratefully acknowledge the financial support, grant, laboratory facility by Biomolecular and Biomedical Research Centre, Aretha Medika Utama, Bandung, West Java, Indonesia. We are also thankful to Seila Arumwardana from Aretha Medika Utama for technical support.

Reference

1. Zhong Y, Chiou YS, Pan MH, Shahidi F. Anti-inflammatory activity of lipophilic epigallocatechin gallate (EGCG) derivatives in LPS-stimulated murine macrophages. *Food Chem.* 2012; 134(2): 742-748.
2. Novilla A, Djamhuri DS, Nurhayati B, Rihibiha DD, Afifah E, Widowati W. Anti-inflammatory properties of oolong tea (*Camellia sinensis*) ethanol extract and epigallocatechin gallate in LPS-induced RAW 264.7 cells. *Asian Pac. J. Trop. Biomed.* 2017; 7(11): 1005–1009.
3. Yuvaraj N, Kanmani P, Satishkumar R, Paari A, Pattukumar V, Arul V. Seagrass as a potential source of natural antioxidant and anti-inflammatory agents. *Pharm. Biol.* 2012; 50(4): 458-467.
4. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. *Curr Biol.* 2014; 24(10): R453-R462.
5. Kattappagari KK, Teja CR, Kommalapati RK, Poosarla C, Gontu SR, Reddy BVR. Role of antioxidants in facilitating the body functions: A review. *J. Orofac. Sci.* 2015; 7(2): 71-75.
6. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. *Antioxid Redox Signal.* 2014;20(7):1126-67.

7. Gupta A, Singh AK, Kumar R, Ganguly R, Rana HK, Pandey PK, Sethi G, Bishayee A, Pandey AK. Corilagin in Cancer: A Critical Evaluation of Anticancer Activities and Molecular Mechanisms. *Molecules*. 2019;24(18):3399.
8. Li Y, Li Z, Hou H, Zhuang Y, Sun L. Metal Chelating, Inhibitory DNA Damage, and Anti-Inflammatory Activities of Phenolics from Rambutan (*Nephelium lappaceum*) Peel and the Quantifications of Geraniin and Corilagin. *Molecules*. 2018;23(9):2263.
9. Pham AT, Malterud KE, Paulsen BS, Diallo D, Wangensteen H. DPPH radical scavenging and xanthine oxidase inhibitory activity of Terminalia macroptera leaves. *Nat. Prod. Commun.* 2011; 6(8): 1125–1128.
10. Jin F, Cheng D, Tao JY, Zhang SL, Pang R, Guo YJ, Ye P, Dong JH, Zhao L. Anti-inflammatory and anti-oxidative effects of corilagin in a rat model of acute cholestasis. *BMC Gastroenterol.* 2013;13:79.
11. Gambari R, Borgatti M, Lampronti I, Fabbri E, Brognara E, Bianchi N, Piccagli L, Yuen MC, Kan CW, Hau DK, Fong WF, Wong WY, Wong RS, Chui CH. Corilagin is a potent inhibitor of NF-kappaB activity and downregulates TNF-alpha induced expression of IL-8 gene in cystic fibrosis IB3-1 cells. *Int Immunopharmacol.* 2012;13(3):308-15.
12. Prahastuti S, Hidayat M, Hasiana ST, Widowati W, Amalia A, Qodariah RL., Rizal R, Kusuma HSW, Khoiriyah Z. Ethanol extract of jati belanda (*Guazuma ulmifolia* L.) as therapy for chronic kidney disease in in vitro model. *J. Rep. Pharm. Sci.* 2019; 8(2): 229-235.
13. Prahastuti S, Hidayat M, Hasiana ST, Widowati W, Widodo WS, Handayani RAS, Rizal R, Kusuma HSW. The ethanol extract of the bastard cedar (*Guazuma ulmifolia* L.) as antioxidants. *Pharmaciana.* 2020; 10(1): 77-88.
14. Irwan M, Girsang E, Nasution AN, Lister INE, Amalia A, Widowati W. Antioxidant activities of black soybean extract (*Glycine max* (L.) Merr.) and daidzein as hydroxyl and nitric oxide scavengers. *Majalah Kedokteran Bandung.* 2020; 52(2): 74-80.
15. Sandhiutami NM, Moordiani M, Laksmiawati DR, Fauziah N, Maesaroh M, Widowati, W. In vitro assesment of anti-inflammatory activities of coumarin and Indonesian cassia extract in RAW264.7 murine macrophage cell line. *Iran. J. Basic Med. Sci.* 2017; 20(1): 99–106.
16. Saanin SN, Wahyudianingsih R, Afni M, Afifah E, Maesaroh M, Widowati W. Suppression of Pro-Inflammatory Cytokines and Mediators Production by Ginger (*Zingiber officinale*) Ethanolic Extract and Gingerol in Lipopolysaccharide-Induced RAW264. 7 Murine Macrophage Cells. *Indian J Nat Prod Resour.* 2021; 11(4): 260-266.
17. Widowati W, Jasaputra DK, Gunawan KY, Kusuma HSW, Arumwardana S, Wahyuni CD, Lister INE, Ginting CN, Girsang E, Rizal R. Turmeric extract potential inhibit inflammatory marker in LPS stimulated macrophage cells. *Int. J. Appl. Pharm.* 2021; 13(3): 7-11.
18. Widowati W, Darsono L, Suherman J, Fauziah N, Maesaroh M, Putu PE. Anti-inflammatory effect of mangosteen (*Garcinia mangostana* L.) peel extract and its compounds in LPS-induced RAW 264.7 cells. *Nat Prod Sci.* 2016; 22(3): 147-53.
19. Widowati W, Prahastuti S, Ekayanti NLW, Munshy UZ, Kusuma HSW, Wibowo SHB, Amalia A, Widodo WS, Rizal R. Anti-inflammation assay of black soybean extract and its compounds on lipopolysaccharide-induced RAW264.7 cell. *J. Phys. Conf.* 2019; 1374: 012052-012063.
20. Ehrich IN, Novalinda C, Girsang E, Dea E, Mardhotillah A, Widowati W. Hepatoprotective properties of red betel (*Piper crocatum* Ruiz and Pav) leaves extract towards H2O2-induced HepG2 cells via anti-inflammatory, antinecrotic, antioxidant potency. *Saudi Pharm. J.* 2020; 28: 1182–1189.

21. Liu S, Wang F, Yan L, Zhang L, Song Y, Xi S, Jia J, Sun G. Oxidative stress and MAPK involved into ATF2 expression in immortalized human urothelial cells treated by arsenic. *Arch Toxicol.* 2013;87(6):981-989.
22. Yakubu OF, Adebayo AH, Iweala EEJ, Adelani IB, Ishola TA, Zhang YJ. Anti-inflammatory and antioxidant activities of fractions and compound from *Riciodendron heudelotii* (Baill.). *Heliyon.* 2019;5(11):e02779.
23. Homayouni-Tabrizi M, Asoodeh A, Soltani M. Cytotoxic and antioxidant capacity of camel milk peptides: Effects of isolated peptide on superoxide dismutase and catalase gene expression. *J Food Drug Anal.* 2017 Jul;25(3):567-575.
24. Bai X, Pan R, Li M, Li X, Zhang H. HPLC Profile of Longan (cv. Shixia) Pericarp-Sourced Phenolics and Their Antioxidant and Cytotoxic Effects. *Molecules.* 2019 Feb 11;24(3):619.
25. Zhang HX, Liu FW, Ren F, Zhang YL, Nie Z. Neuroprotective effect corilagin in spinal cord injury rat model by inhibiting nuclear factor- κ B, inflammation and apoptosis. *Afr J Tradit Complement Altern Med.* 2017; 14(5): 41-48.
26. Li X, Deng Y, Zheng Z, Huang W, Chen L, Tong Q, Ming Y. Corilagin, a promising medicinal herbal agent. *Biomed Pharmacother.* 2018;99:43-50.
27. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol* 2008; 8: 958-69.
28. Ledoux AC, Perkins ND. NF- κ B and the cell cycle. *Biochem Soc Trans* 2014;42:76-81.
29. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. *Cold Spring Harb Perspect Biol.* 2014 Sep 4;6(10):a016295.
30. Li HR, Liu J, Zhang SL, Luo T, Wu F, Dong JH, Guo YJ, Zhao L. Corilagin ameliorates the extreme inflammatory status in sepsis through TLR4 signaling pathways. *BMC Complement Altern Med.* 2017 Jan 5;17(1):18.
31. Levy D. Endogenous mechanisms underlying the activation and sensitization of meningeal nociceptors: the role of immuno-vascular interactions and cortical spreading depression. *Curr. Pain. Headache Rep.* 2012; 16 (3): 270–277.
32. Gambari R, Borgatti M, Lampronti I, Fabbri E, Brognara E, Bianchi N, Piccagli L, Yuen MC, Kan CW, Hau DK, Fong WF, Wong WY, Wong RS, Chui CH. Corilagin is a potent inhibitor of NF- κ B activity and downregulates TNF- α induced expression of IL-8 gene in cystic fibrosis IB3-1 cells. *Int Immunopharmacol.* 2012 Jul;13(3):308-15.
33. Hossain M, Qadri SM, Liu L. Inhibition of nitric oxide synthesis enhances leukocyte rolling and adhesion in human microvasculature. *J Inflamm (Lond).* 2012; 9(1): 28-36.
34. Dal Secco D, Moreira AP, Freitas A, Silva JS, Rossi MA, Ferreira SH, Cunha FQ. Nitric oxide inhibits neutrophil migration by a mechanism dependent on ICAM-1: role of soluble guanylate cyclase. *Nitric oxide.* 2006; 15(1): 77-86.
35. Bueno-Silva B, Marsola A, Ikegaki M, Alencar SM, Rosalen PL. The effect of seasons on Brazilian red propolis and its botanical source: chemical composition and antibacterial activity. *Nat Prod Res.* 2017;31(11): 1318-1324.
36. Reddy BU, Mullick R, Kumar A, Sharma G, Bag P, Roy CL, Sudha G, Tandon H, Dave P, Shukla A, Srinivasan P, Nandhitha M, Srinivasan N, Das S. A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage. *Antiviral Res.* 2018; 150: 47-59.
37. Wu H, Wang Y, Zhang Y, Xu F, Chen J, Duan L, Zhang T, Wang J, Zhang F. Breaking the vicious loop between inflammation, oxidative stress and coagulation, a novel anti-thrombus insight of nattokinase by inhibiting LPS-induced inflammation and oxidative stress. *Redox Biol.* 2020;32:101500.

38. Guo YJ, Zhao L, Li XF, Mei YW, Zhang SL, Tao JY, Zhou Y, Dong JH. Effect of Corilagin on anti-inflammation in HSV-1 encephalitis and HSV-1 infected microglia. *Eur J Pharmacol.* 2010;635(1-3):79-86.
39. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents.* 2020;34(2):327-331.
40. Thangavelu A, Elavarasu S, Sundaram R, Kumar T, Rajendran D, Prem F. Ancient Seed for Modern Cure - Pomegranate Review of Therapeutic Applications in Periodontics. *J Pharm Bioallied Sci.* 2017;9(Suppl 1):S11-S14.
41. Chen JS, Alfajaro MM, Wei J, Chow RD, Filler RB, Eisenbarth SC, Wilen CB. Cyclooxygenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication. *bioRxiv [Preprint].* 2020:2020.09.24.312769.
42. Yoo SR, Jeong SJ, Lee NR, Shin HK, Seo CS. Simultaneous determination and anti-inflammatory effects of four phenolic compounds in *Dendrobii Herba*. *Nat Prod Res.* 2017 Dec;31(24):2923-2926.
43. Salvemini D, Kim SF and Mollace V. Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications. *Am J Physiol Regul Integr Comp Physiol.* 2013; 304: R473-487.
44. Kawata A, Murakami Y, Suzuki S, Fujisawa S. Anti-inflammatory Activity of β -Carotene, Lycopene and Tri-*n*-butylborane, a Scavenger of Reactive Oxygen Species. *In Vivo.* 2018;32(2):255-264.
45. Zhao L, Zhang SL, Tao JY, Pang R, Jin F, Guo YJ, Dong JH, Ye P, Zhao HY, Zheng GH. Preliminary exploration on anti-inflammatory mechanism of Corilagin (beta-1-O-galloyl-3,6-(R)-hexahydroxydiphenoyl-D-glucose) *in vitro*. *Int Immunopharmacol.* 2008; 8(7): 1059-64.
46. Dong XR, Luo M, Fan L, Zhang T, Liu L, Dong JH, Wu G. Corilagin inhibits the double strand break-triggered NF- κ B pathway in irradiated microglial cells. *Int. J. Mol. Med.* 2010; 25(4); 531–536.
47. Napetschnig J, Wu H. Molecular basis of NF-kappaB signaling. *Annu Rev Biophys.* 2013; 42: 443–468.
48. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. *Annu Rev Immunol.* 2009; 27: 693–733.
49. Liu FC, Yu HP, Chou AH, Lee HC, Liao CC. Corilagin reduces acetaminophen-induced hepatotoxicity through MAPK and NF- κ B signaling pathway in a mouse model. *Am J Transl Res.* 2020 Sep 15;12(9):5597-5607.
50. Wancket LM, Meng X, Rogers LK, Liu Y. Mitogen-activated protein kinase phosphatase (Mkp)-1 protects mice against acetaminophen-induced hepatic injury. *Toxicol Pathol.* 2012;40(8):1095-105.
51. Liu FC, Yu HP, Chou AH, Lee HC, Liao CC. Corilagin reduces acetaminophen-induced hepatotoxicity through MAPK and NF- κ B signaling pathway in a mouse model. *Am J Transl Res.* 2020;12(9):5597-5607.

Table and Figure Legends**Table 1.** IC₅₀ value H₂O₂ scavenging activity of corilagin**Table 2.** IC₅₀ value OH scavenging activity of corilagin**Table 3.** IC₅₀ value NO scavenging activity of corilagin**Table 4.** Effect various concentrations of corilagin towards the viability of RAW264.7 cell lines.

*The data was presented as mean ± standard deviation from 3 replications. Different superscript letters in the same column (a, ab, bc, abc, c) showed significant differences among treatments at $p < 0.05$ (Tukey HSD post hoc test).

Figure 1. Effect of corilagin on H₂O₂ scavenging activity

*The data was presented as mean ± standard deviation from 3 replications. Different superscript letters (a, b, ab, bc, d, e) showed significant differences among treatments at $p < 0.05$ (Tukey HSD post hoc test).

Figure 2. Effect of corilagin on OH scavenging activity

*The data was presented as mean ± standard deviation from 3 replications. Different superscripts (a, b, c, d, e) showed significant differences among treatments at $p < 0.05$ (Tukey HSD post hoc test).

Figure 3. Effect of corilagin on NO scavenging activity

*The data was presented as mean ± standard deviation from 3 replications. Different superscripts (a, ab, bc, c, d) showed significant differences among treatments at $p < 0.05$ (Tukey HSD post hoc test).

Figure 4. Effect various concentrations of corilagin towards level and inhibition activity of IL-6 on LPS-induced RAW 264.7 cell lines

(A). IL-6 level (pg/mL). The data was presented as mean ± standard deviation from 3 replications. Different superscript letters (a, b, c, bc, d) for IL-6 level (pg/mL) for IL-6 inhibitory activity showed significant difference among treatments at $p < 0.05$ (Tukey HSD post hoc test). (NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Positive Control + Corilagin 75 μM; Cor 50: Positive Control + Corilagin 50 μM; Cor 25: Positive Control + Corilagin 25 μM).

(B). IL-6 level (pg/mg protein). The data was presented as mean ± standard deviation from 3 replications. Different superscript letters (a, b, c, d) for IL-6 level (pg/mg protein) for IL-6 inhibitory activity showed significant difference among treatments at $p < 0.05$ (Tukey HSD post

hoc test). (NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Positive Control + Corilagin 75 μ M; Cor 50: Positive Control + Corilagin 50 μ M; Cor 25: Positive Control + Corilagin 25 μ M).

(C). IL-6 inhibition activity (%). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, bc, c, d) for IL-6 inhibitory activity showed significant difference among treatments at $p < 0.05$ (Tukey HSD post hoc test). (NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Positive Control + Corilagin 75 μ M; Cor 50: Positive Control + Corilagin 50 μ M; Cor 25: Positive Control + Corilagin 25 μ M).

Figure 5. Effect various concentrations of corilagin towards level and inhibition activity of TNF- α on LPS-induced RAW 264.7 cell lines

(A). TNF- α level (pg/mL). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b) showed significant differences among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M.

(B). TNF- α level (pg/mg protein). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b) showed significant differences among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M.

(C). TNF- α inhibition activity (%). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b) showed significant differences among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M.

Figure 6. Effect various concentrations of corilagin towards level and inhibition activity of NO on LPS-induced RAW 264.7 cell lines.

(A). NO level (pg/mL). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c) showed significant difference among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M.

(B). NO level (pg/mg protein). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c) showed significant difference among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

(C). NO inhibition activity (%). The data was presented as mean \pm standard deviation from 3 replications. NO inhibitory activity showed significant difference among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

Figure 7. Effect various concentrations of corilagin towards level and inhibition activity of IL-1 β on LPS-induced RAW 264.7 cell lines.

(A). IL-1 β level (pg/mL). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, ab) showed significant difference among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

(B). IL-1 β level (pg/mg protein). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b) showed significant difference among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

(C). IL-1 β inhibition activity (%). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, bc) showed significant difference among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

Figure 8. Effect various concentrations of corilagin towards level and inhibition activity of PGE-2 on LPS-induced RAW 264.7 cell lines.

(A). PGE-2 level (pg/mL). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, ab, c) showed significant difference among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

(B). PGE-2 level (pg/mg protein). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, ab, bc, c) showed significant difference among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

(C). PGE-2 inhibition activity (%). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, bc) showed significant difference among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

Figure 9. Effect various concentrations of corilagin towards level and inhibition activity of iNOS on LPS-induced RAW 264.7 cell lines.

(A). iNOS level (pg/mL). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, d) showed significant differences among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

(B). iNOS level (pg/mg protein). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, d) showed significant differences among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

(C). iNOS inhibition activity (%). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, d) showed significant differences among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

Figure 10. Effect various concentrations of corilagin towards level and inhibition activity of COX-2 on LPS-induced RAW 264.7 cell lines.

(A). COX-2 level (pg/mL). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, d, e) showed significant differences among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

(B). COX-2 level (pg/mg protein). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, d, e) showed significant differences among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

(C). COX-2 inhibition activity (%). The data was presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, d, e) for COX-2 inhibitory activity showed significant differences among treatments at $p < 0.05$ (Tukey HSD post hoc test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM ; Cor 50: Corilagin 50 μM ; Cor 25: Corilagin 25 μM .

Figure 11. Effect various concentrations of corilagin toward cells morphological, density in LPS-induced RAW 264.7 cells line.

Figure 12. Proposed mechanism of corilagin effects as an antioxidant and anti-inflammatory activities.

Tables

Table 1.

Sample	Equation	R²	IC₅₀ (µg/mL)
Corilagin	$y = 0.1101x + 41.539$	0.99	76.85

Table 2.

Sample	Equation	R²	IC₅₀ (µg/mL)
Corilagin	$y = 1.292x + 15.524$	0.99	26.68

Table 3.

Sample	Equation	R²	IC₅₀ (µg/mL)
Corilagin	$y = 0.5798x + 11.36$	0.99	66.64

Table 4.

Treatments	Cell Viability (%)
Control	100.00 ± 8.49 ^{bc}
Corilagin 100 µg/mL	78.96 ± 4.46 ^a
Corilagin 75 µg/mL	87.74 ± 2.07 ^{ab}
Corilagin 50 µg/mL	92.59 ± 4.21 ^{abc}
Corilagin 25 µg/mL	102.45 ± 5.14 ^c

Figures

Figure 1




Figure 2.




Figure 3.




Figure 4.




Figure 5.




Figure 6.




Figure 7.




Figure 8.




Figure 9.




Figure 10.




Figure 11.





Figure 12.



Article Acceptance Certificate

This certificate confirms that the following paper has been accepted for publication in
Iranian Journal of Basic Medical Sciences, Volume 24, Issue 12

Title: Corilagin Potential in Inhibiting Stress Oxidative and Inflammatory in LPS-induced
Murine Macrophage Cell Lines (RAW 264.7)

ID: IJBMS-2107-13174 (R1)

Authors: Wahyu Widowati, Hanna Sari Widya Kusuma, Seila Arumwardana, Ervi Afifah,
Cintani Dewi Wahyuni, Muhamad Aldi Maulana, Cahyaning Riski Wijayanti, Rizal Rizal

Submit Date: 29 July 2021

Accept Date: 22 November 2021

Publish Date: 01 December 2021

Fazly Bazzaz, Bibi Sedigheh

Editor-in-Chief of Iranian Journal of Basic Medical Sciences

Corilagin potential in inhibiting oxidative and inflammatory stress in LPS-induced murine macrophage cell lines (RAW 264.7)

Wahyu Widowati^{1*}, Hanna Sari Widya Kusuma², Seila Arumwardana², Ervi Afifah², Cintani Dewi Wahyuni², Cahyaning Riski Wijayanti², Muhamad Aldi Maulana², Rizal Rizal^{2,3}

¹ Faculty of Medicine, Maranatha Christian University, Jl. Surya Sumantri No. 65, Bandung 40164, West Java, Indonesia

² Biomolecular and Biomedical Research Center, Aretha Medika Utama, Jl Babakan Jeruk II No. 9, Bandung 40163, West Java, Indonesia

³ Biomedical Engineering, Department of Electrical Engineering, Faculty of Engineering, Universitas Indonesia, Depok 16426, West Java, Indonesia

ARTICLE INFO

Article type:
Original

Article history:
Received:
Accepted:

Keywords:
Anti-inflammatory
Anti-oxidant
Corilagin
LPS
RAW 264.7

ABSTRACT

Objective(s): Inflammation is thought to be the common pathophysiological basis for several disorders. Corilagin is one of the major active compounds which showed broad-spectrum biological and therapeutic activities, such as antitumor, hepatoprotective, anti-oxidant, and anti-inflammatory. This study aimed to evaluate the anti-oxidant and anti-inflammatory activities of corilagin in LPS-induced RAW264.7 cells.

Materials and Methods: Anti-oxidant activities were examined by free radical scavenging of H₂O₂, NO, and OH. The safe concentrations of corilagin on RAW264.7 were determined by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay on RAW264.7 cell lines. The inflammation cells model was induced with LPS. The anti-inflammatory activities measured IL-6, TNF- α , NO, IL-1 β , PGE-2, iNOS, and COX-2 levels using ELISA assay.

Results: The results showed that corilagin had a significant inhibition activity dose-dependently in scavenging activities toward H₂O₂, OH, and NO with IC₅₀ values 76.85 μ g/ml, 26.68 μ g/ml, and 66.64 μ g/ml, respectively. The anti-inflammatory activity of corilagin also showed a significant decrease toward IL-6, TNF- α , NO, IL-1 β , PGE-2, iNOS, and COX-2 levels at the highest concentration (75 μ M) compared with others concentration (50 and 25 μ M) with the highest inhibition activities being 48.09%, 42.37%, 65.69%, 26.47%, 46.88%, 56.22%, 59.99%, respectively ($P < 0.05$).

Conclusion: Corilagin has potential as anti-oxidant and anti-inflammatory in LPS-induced RAW 264.7 cell lines by its ability to scavenge free radical NO, OH, and H₂O₂, and also suppress the production of proinflammatory mediators including COX-2, IL-6, IL-1 β , and TNF- α in RAW 264.7 murine macrophage cell lines.

► Please cite this article as:

Widowati W, Kusuma HSW, Arumwardana S, Afifah E, Wahyuni CD, Wijayanti CR, Maulana MA, Rizal R. Corilagin potential in inhibiting oxidative and inflammatory stress in LPS-induced murine macrophage cell lines (RAW 264.7). Iran J Basic Med Sci 2021; 24:

Introduction

Over the past two years, inflammation has become a medical concern for researchers, especially those related to COVID-19. Inflammation is a complex mechanical process involving various compounds. Inflammation is a response to irritation and infection caused by pathogens, injury, and chemicals (1, 2). Reactive oxygen species (ROS) such as anion superoxide (O₂⁻), hydroxyl radical ([•]OH), peroxide radicals (ROO), and nitric acid radical (NO) are key signaling molecules that contribute to the progression of inflammatory diseases (3, 4).

Anti-oxidants are the components to neutralize the effect of free radicals, but the effect will be limited to specific anti-oxidants (5). The anti-oxidant agent plays an important role in setting up this intricate balance in the cells (6). The natural bioactive compounds in various plants have anti-oxidant activity. They may help in preventing several inflammatory diseases through free-radical scavenging activity (7). Corilagin was isolated from *Caesalpinia coriaria* (Jacq.) Willd. (dividivi) by Schmidt in 1951 for the first time (8). It was reported to exhibit anti-oxidant (9), anti-cancer

(7), anti-inflammatory, and hepatoprotective activities (10). Previous reports have reported that corilagin can inhibit Tumor Necrosis Factor- α (TNF- α) expression and radiation-stimulated microglia activation by controlling the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF- κ B) pathway (11). Corilagin also has the potential to remedy inflammation and oxidation-related diseases through the capability toward hepatic protection, by blocking the NF- κ B pathway, has anti-oxidative effects, and can act as a hepatoprotective agent (10).

Based on the potential of corilagin, this study evaluates the anti-oxidant and anti-inflammatory activities of corilagin through scavenger ability on H₂O₂, OH, NO, and also inhibitory activity of pro-inflammatory mediators including iNOS, COX-2, IL-6, IL-1 β , and TNF- α in LPS-induced macrophage cells.

Materials and Methods

H₂O₂ scavenging activity assay

Ferrous ammonium sulfate (1 mM, 12 μ l), samples

at various concentrations, and H₂O₂ (5 mM, 3 μ l) were transferred into a 96-well plate and incubated at room temperature for 5 min. Then, 75 μ l of 1,10-phenanthroline was added, and the plate was incubated again for 10 min in the same condition (12, 13). The mixture absorbance was read using a microplate reader at a wavelength of 510 nm and expressed as a percentage of H₂O₂ scavenging activity, which was computed using the equation below:

$$\% \text{ H}_2\text{O}_2 \text{ Scavenging Activity} = (1 - (\text{As}/\text{Ac})) \times 100$$

Ac: Absorbance of negative control

As: Sample absorbance

OH scavenging activity assay

The reaction mixture contained 30 μ l of different concentrations of sample, 10 μ l of FeCl₃-EDTA (Merck, 1.039430250;), 5 μ l of 20 mM H₂O₂ (Merck, 822287), 5 μ l of 1 mM L-Ascorbic acid (Sigma-Aldrich, K3125), 10 μ l of 28 Mm Deoxyribose (Sigma-Aldrich, 121649), and 70 μ l phosphate buffer. The mixture was incubated at 37 °C for 30 min and then 25 μ l of 5% TCA (Merck, 1008070250), and 1% TBA (Sigma-Aldrich, T5500) were added to be further incubated at 80–90 °C for 30 min. The absorbance was measured at 532 nm wavelength using a spectrophotometer (14).

RAW264.7 cell culture

The RAW264.7 (ATCC®TIB-71™) murine macrophage cell line was obtained from the Biomolecular and Biomedical Research Center, Aretha Medika Utama. RAW 264.7 cells were grown in Dulbecco's Modified Eagle Medium (DMEM) (Biowest, L0104) supplemented with 10% fetal bovine serum (FBS) (Biowest, S1810) and 1% antibiotic-antimycotic (Gibco, Massachusetts, USA, 15240062). The cells were incubated at 37 °C and 5% CO₂ in humidified atmosphere until confluent (80%–90%). Trypsin-EDTA 0.25% (Gibco, 25200072) was used to harvest the cells which were then seeded on plates for the assays (2, 8, 15–18).

Viability assay

The cytotoxicity of corilagin was determined by the viability of RAW 264.7 cells using MTS assay (Promega, Madison, G3580). This method determines the safe and nontoxic concentrations of sample for the next assay. Briefly, 100 μ l cells (5×10³ cells per well) in medium (DMEM supplemented with 10% FBS and 1% penicillin-streptomycin) were plated in a 96-well plate and incubated for 24 hr at 37 °C in a humidified atmosphere incubator with 5% CO₂. The medium was then washed and 99 μ l new medium and 1 μ l of corilagin were added in different concentrations and DMSO in triplicate, then the plate was incubated for 24 hr. Untreated cells served as the control. Briefly, 20 μ l MTS was added to each well. The plate was incubated in 5% CO₂ at 37 °C incubator for 4 hr. The absorbance was measured at 490 nm on a microplate reader (2,8,15–19).

Pro-inflammatory activation of RAW264.7 cell lines

The cells were seeded in a 6-well plate at the density of 5 × 10⁵ cells per well and incubated for 24 hr at 37 °C in a humidified atmosphere and 5% CO₂. The medium

(DMEM supplemented with 10% FBS and 1% penicillin-streptomycin) was then washed and supplemented with 1,600 μ l growth medium and 200 μ l corilagin (75, 50, 25 μ M). Around 1–2 hr later, 200 μ l lipopolysaccharide from *Escherichia coli* (LPS) (1 μ g/ml) (Sigma-Aldrich, L2630) was added to the medium and incubated for 24 hr at 37 °C in a humidified atmosphere and 5% CO₂. After incubation of RAW 264.7 cells with LPS for 24 hr, the quantity of IL-6, TNF- α , NO, IL-1 β , PGE-2, iNOS, and COX-2 was accumulated in the cell-free supernatant. The cell-free supernatant then was taken for the next assay by centrifugation at 2,000 g for 10 min. The supernatant was stored at -79 °C for measuring IL-6, TNF- α , NO, IL-1 β , PGE-2, iNOS, and COX-2 levels (2, 15, 17–19).

Quantification of IL-1 β , TNF- α , COX-2, IL-6, PGE-2, and iNOS levels in LPS-Induced RAW 264.7 cells

The IL-1 β , TNF- α , COX-2, IL-6, PGE-2, iNOS levels were assayed using ElabScience Elisa Kit IL-1 β (E-EL-M0037), TNF- α (E-EL-M0049), COX-2 (E-EL-M0959) IL-6 (E-EL-M0044), PGE-2 (E-EL-0034), and iNOS (E-EL-M0696), based on manufacture protocols (2, 8, 15–20).

Quantification of NO level in LPS-induced RAW 264.7 cells

The nitrite associated with NO production was measured using NO Colorimetric Assay (ElabScience, E-BC-K035-M) which was performed based on manufacturing protocols. The sodium nitrite standard curve was determined to measure the nitrite quantity (17).

Total protein assay

Bovine standard albumin (BSA) standard solution was made from dilution series of BSA stock. The stock was obtained by dissolving 2 mg of BSA (Sigma Aldrich, A9576) in 1000 μ l ddH₂O; briefly, 20 μ l of standard solutions and 200 μ l Quick Start Dye Reagen 1X (Biorad, 5000205) was added into each well plate. After 5 min of incubation at room temperature, absorbance was measured by a microplate reader at 595 nm (19, 20).

Statistical analysis

All data were obtained after performing in triplicate. The data were presented as mean \pm standard deviation. The data were analyzed using ANOVA and *post hoc* test using Tukey HSD with *P*<0.05 using SPSS software (version 20.0).

Results

Effect of corilagin on H₂O₂ scavenging activity

Effect of corilagin treatments in H₂O₂ scavenging activity has been shown in Figure 1. Based on Figure 1, The corilagin treatment in concentration 500 μ g/ml showed a significant increase in the inhibitory activity (94.86 \pm 4.90%) compared with other treatment concentrations in H₂O₂ scavenging activity (*P*<0.05). Corilagin also has an IC₅₀ value of H₂O₂ scavenging activity with a value of 76.85 μ g/ml (Table 1). This indicates corilagin has anti-oxidant activity due to H₂O₂ scavenging activity.

Effect of corilagin on OH scavenging activity

The effect of corilagin treatments in the scavenging




Figure 1. Effect of corilagin on H₂O₂ scavenging activity
*The data were presented as mean ± standard deviation from 3 replications. Different superscript letters (a, b, ab, bc, d, e) showed significant differences among treatments at P<0.05 (Tukey HSD post hoc test)

activity of OH can be seen in Figure 2. The inhibitory activity of corilagin shows the highest activity in concentration 26.67 µg/ml with a value of 49.30 ± 3.34% (P<0.05). Corilagin also has an IC₅₀ value of H₂O₂ scavenging activity with a value of 26.68 µg/ml (Table 2), which indicated corilagin has anti-oxidant properties through scavenging OH free radicals.




Figure 2. Effect of corilagin on OH scavenging activity
*The data were presented as mean ± standard deviation from 3 replications. Different superscripts (a, b, c, d, e) showed significant differences among treatments at P<0.05 (Tukey HSD post hoc test)

Effect of corilagin on NO scavenging activity

Effect of corilagin treatments in NO scavenging activity were exhibited in Figure 3. The inhibitory activity of corilagin shows the highest activity in concentration 66.67 µg/ml with a value of 49.73 ± 7.38% (P<0.05). In Table 3, the IC₅₀ value of corilagin as NO scavenger is 66.64 µg/ml. This indicated corilagin has NO scavenging activity.

Effect of corilagin toward RAW264.7 cells viability

The viability of RAW264.7 cell lines is presented in Table 4. The increased concentration was correlated with increasing toxicity (<90% viability cells). Table

Table 1. IC₅₀ value H₂O₂ scavenging activity of corilagin

Sample	Equation	R ²	IC ₅₀ (µg/ml)
Corilagin	y = 0.1101x + 41.539	0.99	76.85

Table 2. IC₅₀ value OH scavenging activity of corilagin

Sample	Equation	R ²	IC ₅₀ (µg/ml)
Corilagin	y = 1.292x + 15.524	0.99	26.68




Figure 3. Effect of corilagin on NO scavenging activity
*The data were presented as mean ± standard deviation from 3 replications. Different superscripts (a, ab, bc, c, d) showed significant differences among treatments at P<0.05 (Tukey HSD post hoc test)

Table 3. IC₅₀ value NO scavenging activity of corilagin

Sample	Equation	R ²	IC ₅₀ (µg/ml)
Corilagin	y = 0.5798x + 11.36	0.99	66.64

Table 4. Effect of various concentrations of corilagin toward the viability of RAW264.7 cell lines

Treatments	Cell Viability (%)
Control	100.00 ± 8.49 ^{bc}
Corilagin 100 µg/ml	78.96 ± 4.46 ^a
Corilagin 75 µg/ml	87.74 ± 2.07 ^{ab}
Corilagin 50 µg/ml	92.59 ± 4.21 ^{abc}
Corilagin 25 µg/ml	102.45 ± 5.14 ^c

*The data were presented as mean ± standard deviation from 3 replications. Different superscript letters in the same column (a, ab, bc, abc, c) showed significant differences among treatments at P<0.05 (Tukey HSD post hoc test)




Figure 4. Effect of various concentrations of corilagin toward level and inhibition activity of IL-6 on LPS-induced RAW 264.7 cell lines (A). IL-6 level (pg/ml). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, bc, d) for IL-6 level (pg/ml) for IL-6 inhibitory activity showed significant difference among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). (NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Positive Control + Corilagin 75 μ M; Cor 50: Positive Control + Corilagin 50 μ M; Cor 25: Positive Control + Corilagin 25 μ M) (B). IL-6 level (pg/mg protein). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, d) for IL-6 level (pg/mg protein) for IL-6 inhibitory activity showed significant difference among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). (NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Positive Control + Corilagin 75 μ M; Cor 50: Positive Control + Corilagin 50 μ M; Cor 25: Positive Control + Corilagin 25 μ M) (C). IL-6 inhibition activity (%). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, bc, c, d) for IL-6 inhibitory activity showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). (NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Positive Control + Corilagin 75 μ M; Cor 50: Positive Control + Corilagin 50 μ M; Cor 25: Positive Control + Corilagin 25 μ M)

4 shows the cytotoxicity of corilagin concentration on RAW264.7 cell lines. The viability of cells was decreased in a dose-dependent manner. Concentration 100 μ g/ml demonstrated the lowest viability of cells by corilagin with a value of $78.96 \pm 4.46\%$ ($P < 0.05$).

Effect of corilagin toward IL-6 level in LPS-induced cells

Essential pro-inflammatory cytokine expression of IL-6 in LPS-induced cells was measured (Figure 4). As shown in Figure 4A, LPS (1 μ g/ml) administration for 24 hr significantly increased this cytokine (635.95 ± 57.77 pg/ml) compared with the negative control group (167.95 ± 27.74 pg/ml). Corilagin treatment in 75 μ M exhibited the decrease of IL-6 level (330.14 ± 33.03 pg/ml; 1523.36 ± 152.42 pg/mg protein) and also showed the highest increase in inhibitory activity in IL-6 level ($48.09 \pm 5.19\%$) compared with positive control and other treatments ($P < 0.05$) (Figures 4A-C).

Effect of corilagin toward TNF- α level in LPS-induced cells

Cytokine expressions of TNF- α in LPS-induced cells were shown in Figure 5. Corilagin at concentration 75 μ M resulted significant decrease TNF- α level ($279.61 \pm$




Figure 5. Effect of various concentrations of corilagin toward level and inhibition activity of TNF- α on LPS-induced RAW 264.7 cell lines (A). TNF- α level (pg/ml). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). (NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M) (B). TNF- α level (pg/mg protein). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). (NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M) (C). TNF- α inhibition activity (%). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). (NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M)

24.95 pg/ml; 129.02 ± 11.51 pg/mg protein). The result was comparable with negative control (218.18 ± 9.41 pg/ml; 106.10 ± 4.58 pg/mg protein) which indicates the treatment has good anti-inflammatory capability (Figures 5A and 5B). The inhibitory activity of TNF- α also shows the highest presentation ($42.37 \pm 5.14\%$) compared with other treatments and positive control ($P < 0.05$) (Figure 5C).

Effect of corilagin toward NO level in LPS-induced cells

The effect of corilagin treatment toward NO level in LPS-induced cells has been shown in Figure 6. Corilagin resulted from the lowest NO level at the highest concentration (75 μ M) with a value of 11.82 ± 2.95 μ M; 54.53 ± 13.60 μ M/mg protein with inhibitory activity of $65.69 \pm 8.56\%$ compared with control and other treatments ($P < 0.05$) (Figures 6A-C). The results demonstrated that corilagin possessed anti-oxidant activity.

Effect of corilagin toward IL-1 β level in LPS-induced cells

The effect of corilagin toward level and inhibitory activity of IL-1 β has been shown in Figure 7. There was




Figure 6. Effect of various concentrations of corilagin toward level and inhibition activity of NO on LPS-induced RAW 264.7 cell lines (A). NO level (pg/ml). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M (B). NO level (pg/mg protein). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M (C). NO inhibition activity (%). The data were presented as mean \pm standard deviation from 3 replications. NO inhibitory activity showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M

significant ($P < 0.05$) decrease in level of IL-1 β (890.00 ± 29.46 pg/ml; 410.67 ± 13.59 pg/mg protein) (Figures 7A and 7B) and increase in inhibitory activity of IL-1 β ($26.47 \pm 2.43\%$) in the highest concentration of corilagin treated group compared with positive control (1210.31 ± 9.57 pg/ml; $0.00 \pm 0.79\%$, respectively) (Figures 7A and 7C).

Effect of corilagin toward PGE-2 level in LPS-induced cells

In the LPS group (positive control) the PGE-2 level was significantly increased (903.15 ± 120.07 pg/ml) when compared with the negative control group (429.42 ± 36.87 pg/ml) ($P < 0.05$). With corilagin intervention, PGE-2 level expression was significantly reduced in the highest concentration (479.76 ± 15.99 pg/ml; $2,213.74 \pm 73.77$ pg/mg protein) (Figures 8A and 8B) and inhibitory percentage of $46.88 \pm 1.77\%$ when compared with the LPS group ($P < 0.05$) (Figure 8C).

Effect of corilagin toward iNOS level in LPS-induced cells

The effect of corilagin on the iNOS level has been shown in Figure 9. The level of iNOS in the positive control group significantly increased before being stimulated




Figure 7. Effect of various concentrations of corilagin toward level and inhibition activity of IL-1 β on LPS-induced RAW 264.7 cell lines (A). IL-1 β level (pg/ml). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, ab) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M (B). IL-1 β level (pg/mg protein). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M (C). IL-1 β inhibition activity (%). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, bc) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M

by LPS (negative control) with values 11.35 ± 0.45 and 3.16 ± 0.04 ng/ml, respectively. Corilagin treatment showed the lowest iNOS level in concentration 75 μ M with value 4.97 ± 0.09 ng/ml; 2.42 ± 0.04 ng/mg protein ($P < 0.05$) compared with another group (Figures 9A and 9B). Corilagin also had the highest inhibitory activity compared with positive control with a value of $56.22 \pm 0.81\%$ (Figure 9C).

Effect of corilagin toward COX-2 level in LPS-induced cells

The effect of corilagin on the COX-2 level has been shown in Figure 10. In the positive control group, the COX-2 level was significantly increased (9.94 ± 0.60 ng/ml) when compared with the negative control group (2.44 ± 0.03 ng/ml) ($P < 0.05$) (Figure 10A). COX-2 level expression was significantly reduced in the highest concentration (75 μ M) with a value of 3.98 ± 29.46 ng/ml; 1.93 ± 0.29 ng/mg protein compared with other treatment and also has inhibitory activity with value $59.99 \pm 6.09\%$ ($P < 0.05$) (Figures 10A-C). Figure 11 shows the effect of various concentrations of corilagin toward cells morphology and density in LPS-induced RAW 264.7 cells line.




Figure 8. Effect of various concentrations of corilagin toward level and inhibition activity of PGE-2 on LPS-induced RAW 264.7 cell lines (A). PGE-2 level (pg/ml). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, ab, c) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M (B). PGE-2 level (pg/mg protein). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, ab, bc, c) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M (C). PGE-2 inhibition activity (%). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, bc) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M

Discussion

Corilagin is a phenolic compound that has been reported to show promising pharmacological effects including anti-inflammatory and anti-oxidant (8, 21). In anti-oxidant activity, concentrated corilagin showed a significant increase in H_2O_2 scavenging activity ($94.86 \pm 4.90\%$) (Figure 1). A Previous study shows corilagin has slightly higher anti-oxidant activity than the standard (vitamin C) and depends on concentration (22).

Free radicals such as hydroxyl radicals (OH) and superoxide anion radicals can be generated by normal physiological reactions in living organisms (23). In recent studies, corilagin has OH inhibitory activity in a dose-dependent manner with the highest value ($49.30 \pm 3.34\%$) (Figure 2). Another study has reported that corilagin isolated from longan pericarp extract possessed the highest OH inhibitory rate of $75.90 \pm 0.30\%$ compared with other phenolic compounds, and also has DPPH radical scavenging rate of $71.80 \pm 0.50\%$ (24). Corilagin showed anti-oxidative activity due to scavenging of nitrite and blocking of nitrosamine synthesis (8). Corilagin significantly reduces oxidative




Figure 9. Effect of various concentrations of corilagin toward level and inhibition activity of iNOS on LPS-induced RAW 264.7 cell lines (A). iNOS level (pg/ml). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, d) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M (B). iNOS level (pg/mg protein). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, d) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M (C). iNOS inhibition activity (%). The data were presented as mean \pm standard deviation from 3 replications. Different superscript letters (a, b, c, d) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μ M; Cor 50: Corilagin 50 μ M; Cor 25: Corilagin 25 μ M

stress by increasing the total anti-oxidant capacity and decreasing malondialdehyde (MDA) in the spinal tissue injured rat. Corilagin treatment also decreases the concentration of cytokines in the spinal tissue of spinal cord injured rats. Oxidative stress and inflammatory mediators trigger the activity of caspase cascade and result in increased activity of caspase 3, Bax, and a decrease in Bcl-2 in injured spinal cord tissues (25).

The anti-oxidant effect of corilagin also was measured by its inhibitory potency on nitric oxide (NO). In this study, corilagin shows the highest NO scavenging activity is $49.73 \pm 7.38\%$ in a concentration of 66.67μ g/ml ($P < 0.05$) (Figure 3). Corilagin was shown to exhibit NO scavenging activity with IC_{50} 7.2 μ M (26).

In this study, the cytotoxic assay was performed on RAW 264.7 cells to rule out any adverse effects before using corilagin. Based on the results of cytotoxic (viability cell) assays, corilagin treatment showed not toxicity and is safe in concentrations 75, 50, and 25 μ M.

LPS-induced in macrophage cell lines (RAW 264.7) as pro-inflammatory activation caused the increase in inflammatory cytokines IL-6, TNF- α , NO, IL-1 β , PGE-2,




Figure 10. Effect of various concentrations of corilagin toward level and inhibition activity of COX-2 on LPS-induced RAW 264.7 cell lines. (A). COX-2 level (pg/ml). The data were presented as mean ± standard deviation from 3 replications. Different superscript letters (a, b, c, d, e) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM; Cor 50: Corilagin 50 μM; Cor 25: Corilagin 25 μM (B). COX-2 level (pg/mg protein). The data were presented as mean ± standard deviation from 3 replications. Different superscript letters (a, b, c, d, e) showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM; Cor 50: Corilagin 50 μM; Cor 25: Corilagin 25 μM (C). COX-2 inhibition activity (%). The data were presented as mean ± standard deviation from 3 replications. Different superscript letters (a, b, c, d, e) for COX-2 inhibitory activity showed significant differences among treatments at $P < 0.05$ (Tukey HSD *post hoc* test). NC: Negative Control (untreated cell); PC: Positive Control (LPS-induced cell); Cor 75: Corilagin 75 μM; Cor 50: Corilagin 50 μM; Cor 25: Corilagin 25 μM

iNOS, and COX-2 (2, 7.8, 8.20, 9.15, 10.16, 12.17, 25.18, and 26.19, respectively). In this study, the inflammation model using LPS-induced cells as a positive control indicated increasing of inflammatory cytokines such as IL-6, TNF-α, NO, IL-1β, PGE-2, iNOS, and COX-2 compared with the negative control. Macrophages become activated and produce pro-inflammatory mediators through the extracellular region of Toll-Like receptor 4 (TLR4), which will become activated through the MAPK (JNK, ERK1/2, p38) pathway (17, 27). The activated TLR4 will activate cascade events in the cytoplasm which leads to MAPK (JNK, ERK1/2, p38) pathway activation. The phosphorylation of MAPKs allows the inhibitory factor-kappa B (IκB) to be phosphorylated. Nuclear factor-kappa B (NF-κB) is activated and translocated to the nucleus as a result of this. NFκB is a widely distributed transcription factor that regulates the expression of genes involved in apoptosis, immune responses, and the cell cycle (17, 28).

IL-6 is a monocyte-derived cytokine, these have an important acute phase reaction medium in inducing the inflammation process (29). Corilagin treatment in a concentration of 75 μM showed the highest inhibitory activity in the IL-6 level ($48.09 \pm 5.19\%$) compared with positive control and other treatments (Figure 4C). Corilagin possessed anti-inflammatory




Figure 11. Effect of various concentrations of corilagin toward cells morphological, density in LPS-induced RAW 264.7 cells line




Figure 12. Proposed mechanism of corilagin effects as anti-oxidant and anti-inflammatory activity

capability, through intervention the expression of TLR4 was greatly decreased in the inflammatory phase. Corilagin intervention, IL-1β, and IL-6 expression were significantly reduced when compared with the LPS group ($P < 0.01$) (30).

TNF-α is a highly inflammatory cytokine developed and secreted by mast cells and plays a key role in some pathogenesis (31, 8, 17). In the present study, we have demonstrated that corilagin has anti-inflammatory activity due to suppressing of TNF-α level ($42.37 \pm 5.14\%$) compared with other treatments (Figure 5C). This result is in line with Gambari *et al.* (2012) study that showed corilagin can inhibit the expression of (TNF-α) and interleukin (IL)-6 protein (32).

Several mediators, including nitric oxide (NO), control leukocyte recruitment to the infection site. NO is a vascular tone regulator that also controls leukocyte adherence in blood micro-capillaries (33-35). Corilagin can suppress NO level with a percentage of 65.69 ± 8.56 (Figure 6C). The previous reports demonstrated that corilagin suppresses the levels of NO and modulates oxidative stress to reduce liver damage induced by HCV proteins (36). Corilagin also elicited prominent anti-inflammatory activity in RAW264.7 macrophages via suppressing LPS-induced TLR4 and NOX2 activation, thereby repressing the corresponding ROS production,

MAPKs activation, and NF- κ B translocation from the cytoplasm to the nucleus, where it mediates the expression of pro-inflammatory mediators, such as TNF- α , IL-6, NO, and PAI-1 in activated macrophage cells (37). Moreover, corilagin lightened the herpes simplex virus (HSV)-1-induced inflammatory damage by inducing the apoptosis of infected microglial cells and inhibiting the production of TNF- α , NO, and IL-1 β (38).

IL-1B production caused Toll-like receptor (TLR) activation and also stimulated up-regulation of NF- κ B in inflammatory diseases (39). This study demonstrated that corilagin has IL-1 β inhibitory activity ($26.47 \pm 2.43\%$) (Figure 7C). Corilagin in pomegranate fruit has been shown to inhibit inducible nitric oxide synthase expression and IL-1B-induced tissue destruction in periodontitis (40).

Prostaglandin E2 (PGE₂) is a pro-inflammatory lipid mediator produced by cyclooxygenase-2 (COX-2) and microsomal PGE synthase-1 from arachidonic acid (mPGES-1) (41). The present study showed that corilagin can act as a PGE-2 inhibitor ($46.88 \pm 1.77\%$) (Figure 8C). Phenolic compounds like corilagin can reduce LPS-stimulated PGE₂ production, they exhibit anti-inflammatory activity by targeting different inflammation-related cytokines (42).

Inflammatory activity is accompanied by inducible nitric oxide synthase (iNOS), which produces nitric oxide, which stimulates COX-2 catalytic activity by forming peroxy nitrite anion. (43, 44). Stimuli that increase NOS-2 and NO formation also may induce COX-2 expression (44). In this study, iNOS pro-inflammatory activity had a percentage of $56.22 \pm 0.81\%$ (Figure 9C), while COX-2 level had a value of $59.99 \pm 6.09\%$ (Figure 10C); all had the highest value compared with positive control and other concentration in LPS-induced cells. Similar results were obtained by Zhao *et al.* (2008), who found that corilagin repressed the discharge of the pro-inflammatory cytokines COX-2 and NO (iNOS) through inhibiting the NF- κ B pathway in LPS-stimulated RAW 264.7 (45). Corilagin also can inhibit the production of pro-inflammatory cytokines and mediators including COX-2 through suppressing the DSBs (DNA double-strand breaks)-triggered NF- κ B signaling pathway in the murine microglial cell line (BV-2) (46).

The morphological change in macrophage RAW 264.7 cells was induced by LPS and treated with various concentrations of corilagin (75, 50, 25 μ M), furthermore incubated for 24 hr. (Figure 11). The negative control (normal cells, without LPS) was a round shape, the positive control became irregularly shaped, and increased spreading after LPS stimulation. The cotreatment with 25, 50, and 75 μ M corilagin decreased the degree of cell spreading and irregular shape. Treatment of 75 μ M corilagin was the most active to decrease the spreading and density of cells. There result data were in line with previous research showing that LPS stimulation changed the cells' round shape to irregular and increased the spreading of cells.

The anti-oxidant activities possibly contribute to the polyphenol compound found in corilagin, major active polyphenolic tannins (26). Oxidative stress has played a role in activating signal pathways such as NF- κ B, an important transcription factor in the nucleus. The excessive oxidative stress release caused NF- κ B

activation, and then nuclear translocation and binding specific sites in the promoter regions of target genes. It up-regulates gene expressions of numerous pro-inflammatory cytokines and inflammatory mediators including TNF- α , IL-1 β , and COX-2 (47-49). However, corilagin has protective effects against LPS-induced RAW264.7 cell lines by suppressing ERK/JNK MAPK and NF- κ B signaling pathways. Moreover, the inflammatory mediators and ROS have been related to the actuation of mitogen-activated protein kinase (MAPK) that controls the intracellular signal transduction pathway in oxidative stress-induced cells (50). Its mechanism is attributed to anti-inflammatory and anti-oxidative properties (37). In summary, corilagin may play a critical part in the oxidative stress and inflammatory response (51). Based on these results, we proposed anti-oxidant and anti-inflammatory mechanism of corilagin in LPS-stimulated RAW264.7 cells (Figure 12).

Conclusion

Corilagin has the potential as an anti-oxidant as measured through H₂O₂, NO, and OH inhibitory activities. Corilagin also has anti-inflammatory properties through suppression of IL-6, TNF- α , NO, IL-1 β , PGE-2, iNOS, and COX-2 levels. However, corilagin protects against LPS-stimulated RAW264.7 cells via inhibiting oxidative stress and inflammation. This study can be the basis for further research on the exploration of the bioactivity of corilagin and on the treatment of inflammatory diseases with natural compounds.

Acknowledgment

The authors gratefully acknowledge the financial support, grant, and the laboratory facility by Biomolecular and Biomedical Research Centre, Aretha Medika Utama, Bandung, West Java, Indonesia. We are also thankful to Seila Arumwardana from Aretha Medika Utama for technical support.

Authors' Contributions

WW, SA, and HSWK Study conception and design; HS WK, CDW, MAM, and CRW Data analysis and draft manuscript preparation; WW, HSWK, and CRW Critical revision of the paper; EA and CDW Supervision of the research; WW, HSWK, EA, and RR Final approval of the version to be published.

Conflicts of Interest

The authors declare that no conflict of interest exists.

References

- Zhong Y, Chiou YS, Pan MH, Shahidi F. Anti-inflammatory activity of lipophilic epigallocatechin gallate (EGCG) derivatives in LPS-stimulated murine macrophages. *Food Chem.* 2012; 134(2): 742-748.
- Novilla A, Djamhuri DS, Nurhayati B, Rihibiha DD, Afifah E, Widowati W. Anti-inflammatory properties of oolong tea (*Camellia sinensis*) ethanol extract and epigallocatechin gallate in LPS-induced RAW 264.7 cells. *Asian Pac. J. Trop. Biomed.* 2017; 7(11): 1005-1009.
- Yuvaraj N, Kanmani P, Satishkumar R, Paari A, Pattukumar V, Arul V. Seagrass as a potential source of natural anti-oxidant and anti-inflammatory

- agents. *Pharm. Biol.* 2012; 50(4): 458-467.
4. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. *Curr Biol.* 2014; 24(10): R453-R462.
 5. Kattappagari KK, Teja CR, Kommalapati RK, Poosarla C, Gontu SR, Reddy BVR. Role of anti-oxidants in facilitating the body functions: A review. *J. Orofac. Sci.* 2015; 7(2): 71-75.
 6. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. *Anti-oxid Redox Signal.* 2014;20(7):1126-67.
 7. Gupta A, Singh AK, Kumar R, Ganguly R, Rana HK, Pandey PK, Sethi G, Bishayee A, Pandey AK. Corilagin in Cancer: A Critical Evaluation of Anticancer Activities and Molecular Mechanisms. *Molecules.* 2019;24(18):3399.
 8. Li Y, Li Z, Hou H, Zhuang Y, Sun L. Metal Chelating, Inhibitory DNA Damage, and Anti-Inflammatory Activities of Phenolics from Rambutan (*Nephelium lappaceum*) Peel and the Quantifications of Geraniin and Corilagin. *Molecules.* 2018;23(9):2263.
 9. Pham AT, Malterud KE, Paulsen BS, Diallo D, Wangensteen H. DPPH radical scavenging and xanthine oxidase inhibitory activity of Terminalia macroptera leaves. *Nat. Prod. Commun.* 2011; 6(8): 1125-1128.
 10. Jin F, Cheng D, Tao JY, Zhang SL, Pang R, Guo YJ, Ye P, Dong JH, Zhao L. Anti-inflammatory and anti-oxidative effects of corilagin in a rat model of acute cholestasis. *BMC Gastroenterol.* 2013;13:79.
 11. Gambari R, Borgatti M, Lampronti I, Fabbri E, Brognara E, Bianchi N, Piccagli L, Yuen MC, Kan CW, Hau DK, Fong WF, Wong WY, Wong RS, Chui CH. Corilagin is a potent inhibitor of NF-kappaB activity and downregulates TNF-alpha induced expression of IL-8 gene in cystic fibrosis IB3-1 cells. *Int Immunopharmacol.* 2012;13(3):308-15.
 12. Prahastuti S, Hidayat M, Hasiana ST, Widowati W, Amalia A, Qodariah RL, Rizal R, Kusuma HSW, Khoiriyah Z. Ethanol extract of jati belanda (*Guazuma ulmifolia* L.) as therapy for chronic kidney disease in in vitro model. *J. Rep. Pharm. Sci.* 2019; 8(2): 229-235.
 13. Prahastuti S, Hidayat M, Hasiana ST, Widowati W, Widodo WS, Handayani RAS, Rizal R, Kusuma HSW. The ethanol extract of the bastard cedar (*Guazuma ulmifolia* L.) as anti-oxidants. *Pharmaciana.* 2020; 10(1): 77-88.
 14. Irwan M, Girsang E, Nasution AN, Lister INE, Amalia A, Widowati W. Anti-oxidant activities of black soybean extract (*Glycine max* (L.) Merr.) and daidzein as hydroxyl and nitric oxide scavengers. *Majalah Kedokteran Bandung.* 2020; 52(2): 74-80.
 15. Sandhiutami NM, Moordiani M, Laksmiawati DR, Fauziah N, Maesaroh M, Widowati W. In vitro assesment of anti-inflammatory activities of coumarin and Indonesian cassia extract in RAW264.7 murine macrophage cell line. *Iran. J. Basic Med. Sci.* 2017; 20(1): 99-106.
 16. Saanin SN, Wahyudianingsih R, Afni M, Afifah E, Maesaroh M, Widowati W. Suppression of Pro-Inflammatory Cytokines and Mediators Production by Ginger (*Zingiber officinale*) Ethanolic Extract and Gingerol in Lipopolysaccharide-Induced RAW264.7 Murine Macrophage Cells. *Indian J Nat Prod Resour.* 2021; 11(4): 260-266.
 17. Widowati W, Jasaputra DK, Gunawan KY, Kusuma HSW, Arumwardana S, Wahyuni CD, Lister INE, Ginting CN, Girsang E, Rizal R. Turmeric extract potential inhibit inflammatory marker in LPS stimulated macrophage cells. *Int. J. Appl. Pharm.* 2021; 13(3): 7-11.
 18. Widowati W, Darsono L, Suherman J, Fauziah N, Maesaroh M, Putu PE. Anti-inflammatory effect of mangosteen (*Garcinia mangostana* L.) peel extract and its compounds in LPS-induced RAW 264.7 cells. *Nat Prod Sci.* 2016; 22(3): 147-53.
 19. Widowati W, Prahastuti S, Ekayanti NLW, Munshy UZ, Kusuma HSW, Wibowo SHB, Amalia A, Widodo WS, Rizal R. Anti-inflammation assay of black soybean extract and its compounds on lipopolysaccharide-induced RAW264.7 cell. *J. Phys. Conf.* 2019; 1374: 012052-012063.
 20. Ehrlich IN, Novalinda C, Girsang E, Dea E, Mardhotillah A, Widowati W. Hepatoprotective properties of red betel (*Piper crocatum* Ruiz and Pav) leaves extract towards H2O2-induced HepG2 cells via anti-inflammatory, antineurotic, anti-oxidant potency. *Saudi Pharm. J.* 2020; 28: 1182-1189.
 21. Liu S, Wang F, Yan L, Zhang L, Song Y, Xi S, Jia J, Sun G. Oxidative stress and MAPK involved into ATF2 expression in immortalized human urothelial cells treated by arsenic. *Arch Toxicol.* 2013;87(6):981-989.
 22. Yakubu OF, Adebayo AH, Iweala EE, Adelani IB, Ishola TA, Zhang YJ. Anti-inflammatory and anti-oxidant activities of fractions and compound from *Ricinodendron heudelotii* (Baill.). *Heliyon.* 2019;5(11):e02779.
 23. Homayouni-Tabrizi M, Asoodeh A, Soltani M. Cytotoxic and anti-oxidant capacity of camel milk peptides: Effects of isolated peptide on superoxide dismutase and catalase gene expression. *J Food Drug Anal.* 2017 Jul;25(3):567-575.
 24. Bai X, Pan R, Li M, Li X, Zhang H. HPLC Profile of Longan (cv. Shixia) Pericarp-Sourced Phenolics and Their Anti-oxidant and Cytotoxic Effects. *Molecules.* 2019 Feb 11;24(3):619.
 25. Zhang HX, Liu FW, Ren F, Zhang YL, Nie Z. Neuroprotective effect corilagin in spinal cord injury rat model by inhibiting nuclear factor-kB, inflammation and apoptosis. *Afr J Tradit Complement Altern Med.* 2017; 14(5): 41-48.
 26. Li X, Deng Y, Zheng Z, Huang W, Chen L, Tong Q, Ming Y. Corilagin, a promising medicinal herbal agent. *Biomed Pharmacother.* 2018;99:43-50.
 27. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol* 2008; 8: 958-69.
 28. Ledoux AC, Perkins ND. NF-kB and the cell cycle. *Biochem Soc Trans* 2014;42:76-81.
 29. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. *Cold Spring Harb Perspect Biol.* 2014 Sep 4;6(10):a016295.
 30. Li HR, Liu J, Zhang SL, Luo T, Wu F, Dong JH, Guo YJ, Zhao L. Corilagin ameliorates the extreme inflammatory status in sepsis through TLR4 signaling pathways. *BMC Complement Altern Med.* 2017 Jan 5;17(1):18.
 31. Levy D. Endogenous mechanisms underlying the activation and sensitization of meningeal nociceptors: the role of immuno-vascular interactions and cortical spreading depression. *Curr Pain. Headache Rep.* 2012; 16 (3): 270-277.
 32. Gambari R, Borgatti M, Lampronti I, Fabbri E, Brognara E, Bianchi N, Piccagli L, Yuen MC, Kan CW,

- Hau DK, Fong WF, Wong WY, Wong RS, Chui CH. Corilagin is a potent inhibitor of NF-kappaB activity and downregulates TNF-alpha induced expression of IL-8 gene in cystic fibrosis IB3-1 cells. *Int Immunopharmacol*. 2012 Jul;13(3):308-15.
33. Hossain M, Qadri SM, Liu L. Inhibition of nitric oxide synthesis enhances leukocyte rolling and adhesion in human microvasculature. *J Inflamm (Lond)*. 2012; 9(1): 28-36.
34. Dal Secco D, Moreira AP, Freitas A, Silva JS, Rossi MA, Ferreira SH, Cunha FQ. Nitric oxide inhibits neutrophil migration by a mechanism dependent on ICAM-1: role of soluble guanylate cyclase. *Nitric oxide*. 2006; 15(1): 77-86.
35. Bueno-Silva B, Marsola A, Ikegaki M, Alencar SM, Rosalen PL. The effect of seasons on Brazilian red propolis and its botanical source: chemical composition and antibacterial activity. *Nat Prod Res*. 2017;31(11): 1318-1324.
36. Reddy BU, Mullick R, Kumar A, Sharma G, Bag P, Roy CL, Sudha G, Tandon H, Dave P, Shukla A, Srinivasan P, Nandhitha M, Srinivasan N, Das S. A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage. *Antiviral Res*. 2018; 150: 47-59.
37. Wu H, Wang Y, Zhang Y, Xu F, Chen J, Duan L, Zhang T, Wang J, Zhang F. Breaking the vicious loop between inflammation, oxidative stress and coagulation, a novel anti-thrombus insight of nattokinase by inhibiting LPS-induced inflammation and oxidative stress. *Redox Biol*. 2020;32:101500.
38. Guo YJ, Zhao L, Li XF, Mei YW, Zhang SL, Tao JY, Zhou Y, Dong JH. Effect of Corilagin on anti-inflammation in HSV-1 encephalitis and HSV-1 infected microglia. *Eur J Pharmacol*. 2010;635(1-3):79-86.
39. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents*. 2020;34(2):327-331.
40. Thangavelu A, Elavarasu S, Sundaram R, Kumar T, Rajendran D, Prem F. Ancient Seed for Modern Cure - Pomegranate Review of Therapeutic Applications in Periodontics. *J Pharm Bioallied Sci*. 2017;9(Suppl 1):S11-S14.
41. Chen JS, Alfajaro MM, Wei J, Chow RD, Filler RB, Eisenbarth SC, Wilen CB. Cyclooxygenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication. *bioRxiv [Preprint]*. 2020:2020.09.24.312769.
42. Yoo SR, Jeong SJ, Lee NR, Shin HK, Seo CS. Simultaneous determination and anti-inflammatory effects of four phenolic compounds in *Dendrobii Herba*. *Nat Prod Res*. 2017 Dec;31(24):2923-2926.
43. Salvemini D, Kim SF and Mollace V. Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications. *Am J Physiol Regul Integr Comp Physiol*. 2013; 304: R473-487.
44. Kawata A, Murakami Y, Suzuki S, Fujisawa S. Anti-inflammatory Activity of β -Carotene, Lycopene and Tri-*n*-butylborane, a Scavenger of Reactive Oxygen Species. *In Vivo*. 2018;32(2):255-264.
45. Zhao L, Zhang SL, Tao JY, Pang R, Jin F, Guo YJ, Dong JH, Ye P, Zhao HY, Zheng GH. Preliminary exploration on anti-inflammatory mechanism of Corilagin (beta-1-O-galloyl-3,6-(R)-hexahydroxydiphenoyl-D-glucose) in vitro. *Int Immunopharmacol*. 2008; 8(7): 1059-64.
46. Dong XR, Luo M, Fan L, Zhang T, Liu L, Dong JH, Wu G. Corilagin inhibits the double strand break-triggered NF- κ B pathway in irradiated microglial cells. *Int. J. Mol. Med*. 2010; 25(4); 531-536.
47. Napetschnig J, Wu H. Molecular basis of NF-kappaB signaling. *Annu Rev Biophys*. 2013; 42: 443-468.
48. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. *Annu Rev Immunol*. 2009; 27: 693-733.
49. Liu FC, Yu HP, Chou AH, Lee HC, Liao CC. Corilagin reduces acetaminophen-induced hepatotoxicity through MAPK and NF- κ B signaling pathway in a mouse model. *Am J Transl Res*. 2020 Sep 15;12(9):5597-5607.
50. Wancket LM, Meng X, Rogers LK, Liu Y. Mitogen-activated protein kinase phosphatase (Mkp)-1 protects mice against acetaminophen-induced hepatic injury. *Toxicol Pathol*. 2012;40(8):1095-105.
51. Liu FC, Yu HP, Chou AH, Lee HC, Liao CC. Corilagin reduces acetaminophen-induced hepatotoxicity through MAPK and NF- κ B signaling pathway in a mouse model. *Am J Transl Res*. 2020;12(9):5597-5607.